RT Journal Article
SR Electronic
T1 1191 ATG-021, a novel 2+1 CD3-based T cell engager (TCE) targeting GPRC5D, demonstrates potent <em>in vivo</em> anti-tumor efficacy with low cytokine release
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A1312
OP A1313
DO 10.1136/jitc-2023-SITC2023.1191
VO 11
IS Suppl 1
A1 Yuwen, Hui
A1 Li, Tengteng
A1 Ren, Yijing
A1 Mei, Jay
A1 Shan, Bo
A1 Hou, Bing
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A1312.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.